SG Americas Securities LLC Has $546,000 Holdings in Glaukos Co. (NYSE:GKOS)

SG Americas Securities LLC raised its position in shares of Glaukos Co. (NYSE:GKOS) by 42.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,641 shares of the medical instruments supplier’s stock after buying an additional 1,078 shares during the period. SG Americas Securities LLC’s holdings in Glaukos were worth $546,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in Glaukos by 5.4% during the 2nd quarter. AQR Capital Management LLC now owns 4,141 shares of the medical instruments supplier’s stock valued at $490,000 after purchasing an additional 211 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Glaukos by 7.5% during the second quarter. The Manufacturers Life Insurance Company now owns 27,711 shares of the medical instruments supplier’s stock worth $3,280,000 after purchasing an additional 1,926 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Glaukos in the second quarter valued at $598,000. Creative Planning raised its holdings in shares of Glaukos by 126.8% in the second quarter. Creative Planning now owns 7,706 shares of the medical instruments supplier’s stock valued at $912,000 after buying an additional 4,309 shares during the last quarter. Finally, Truist Financial Corp lifted its position in Glaukos by 8.8% during the 2nd quarter. Truist Financial Corp now owns 18,478 shares of the medical instruments supplier’s stock worth $2,187,000 after buying an additional 1,490 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Glaukos stock opened at $156.61 on Friday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $8.64 billion, a P/E ratio of -51.86 and a beta of 1.04. The business has a 50-day moving average of $149.41 and a 200-day moving average of $136.01. Glaukos Co. has a 1 year low of $83.90 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.50) earnings per share. On average, equities analysts anticipate that Glaukos Co. will post -1.89 EPS for the current year.

Insiders Place Their Bets

In related news, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,859,454.08. The trade was a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,328 shares of company stock worth $2,289,521. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of several research reports. BTIG Research raised their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and raised their price target for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Stephens upgraded Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Wells Fargo & Company boosted their target price on Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $151.08.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.